abstract |
The present invention relates to a pharmaceutical composition comprising the synergistic combination of an NMDA receptor antagonist agent, such as the active ingredient: ketamine and an MT1 and MT2 melatonin receptor agonist agent, such as the active ingredient: Melatonin, which are in a pharmaceutical composition, which is indicated for the control and treatment of psychiatric diseases. |